Issue 104 • March 2021

HeLa: the legacy of Henrietta Lacks 

Treating Covid-19 symptoms in the GI tract

A history of antibody-drug conjugates 

Getting the skinny on generics labelling

An ongoing court battle over skinny labelling practices could mean trouble for the future of generics manufacturers

In association with

02/23/2024 23:26:12
  • Home | Getting the skinny on generics labelling
  • In this issue
  • Contents
  • HOF Sonderanlagenbau Company Insight
  • HOF Sonderanlagenbau
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Covid-19 executive briefing by GlobalData
  • Mimotopes Company Insight
  • Mimotopes
  • The Solubility company
  • The Solubility Company Insight
  • Comment
  • Market access of orphan designated therapies at risk
  • Lodo Therapeutics’ AI-driven natural drug discovery platform
  • Concert Pharmaceuticals discontinues schizophrenia drug after trial failure
  • Medical cannabis in Europe: a compelling opportunity
  • Exploring the pharma deals outlook in 2021
  • In Depth
  • Skinny labelling of generics: the beginning of the end for this practice?
  • Charting the choppy history of ‘magic bullet’ antibody-drug conjugates
  • How a sleeping drug awakened a patient with akinetic mutism
  • Breast cancer research: addressing the pre-menopausal problem
  • Beyond the lung: treating the GI symptoms of Covid-19
  • Immortal cells and informed consent: the legacy of Henrietta Lacks
  • How radiopharmaceuticals are helping fight cancer with Fusion
  • Competition heats up as new HIV prevention drug shows promise
  • Baxter
  • ACG Worldwide
  • In Data
  • Inside the deal
  • Deals analysis
  • The pharma industry key list
  • Global markets and indices
  • Macro-economic indicators
  • Macro-economic indicators (page 2)
  • Events
  • Next issue
02/17/2021 00:00:00